• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用秀丽隐杆线虫作为模式生物来研究与帕金森病相关的分子途径。

C. elegans as a model organism to investigate molecular pathways involved with Parkinson's disease.

机构信息

Department of Biological Sciences, The University of Alabama, Tuscaloosa, Alabama 35487-0344, USA.

出版信息

Dev Dyn. 2010 May;239(5):1282-95. doi: 10.1002/dvdy.22231.

DOI:10.1002/dvdy.22231
PMID:20108318
Abstract

Parkinson's disease (PD) is an age-related movement disorder resulting, in part, from selective loss of dopaminergic neurons. Both invertebrate and mammalian models have been developed to study the cellular mechanisms altered during disease progression; nevertheless there are limitations within each model. Mammalian models remain invaluable in studying PD, but are expensive and time consuming. Here, we review genetic and environmental factors associated with PD, and describe how the nematode roundworm, Caenorhabditis elegans, has been used as a model organism for studying various aspects of this neurodegenerative disease. Both genetic and chemical screens have been conducted in C. elegans to identify molecular pathways, proteins, and small molecules that can impact PD pathology. Lastly, we highlight future areas of investigation, in the context of emerging fields in biology, where the nematode can be exploited to provide mechanistic insights and potential strategies to accelerate the path toward possible therapeutic intervention for PD.

摘要

帕金森病(PD)是一种与年龄相关的运动障碍,部分原因是多巴胺能神经元的选择性丧失。已经开发了无脊椎动物和哺乳动物模型来研究疾病进展过程中改变的细胞机制;然而,每种模型都有其局限性。哺乳动物模型在研究 PD 方面仍然具有不可估量的价值,但成本高且耗时。在这里,我们回顾了与 PD 相关的遗传和环境因素,并描述了秀丽隐杆线虫如何被用作研究这种神经退行性疾病各个方面的模式生物。已经在秀丽隐杆线虫中进行了遗传和化学筛选,以鉴定可能影响 PD 病理学的分子途径、蛋白质和小分子。最后,我们强调了未来的研究领域,涉及生物学的新兴领域,线虫可以被利用来提供机制见解和潜在策略,以加速 PD 可能的治疗干预的研究。

相似文献

1
C. elegans as a model organism to investigate molecular pathways involved with Parkinson's disease.利用秀丽隐杆线虫作为模式生物来研究与帕金森病相关的分子途径。
Dev Dyn. 2010 May;239(5):1282-95. doi: 10.1002/dvdy.22231.
2
Caenorhabditis elegans as a model system for Parkinson's disease.秀丽隐杆线虫作为帕金森病的模型系统。
Neurodegener Dis. 2007;4(2-3):199-217. doi: 10.1159/000101845.
3
Caenohabditis elegans in Parkinson's disease drug discovery: addressing an unmet medical need.秀丽隐杆线虫在帕金森病药物研发中的应用:满足未被满足的医疗需求
Mol Interv. 2008 Dec;8(6):284-93. doi: 10.1124/mi.8.6.6.
4
Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease.对乙酰氨基酚可减轻帕金森病动物模型中的多巴胺能神经元变性。
Neurosci Lett. 2008 Jul 11;439(2):129-33. doi: 10.1016/j.neulet.2008.05.003. Epub 2008 May 7.
5
Caenorhabditis elegans as a model system for identifying effectors of α-synuclein misfolding and dopaminergic cell death associated with Parkinson's disease.秀丽隐杆线虫作为鉴定与帕金森病相关的α-突触核蛋白错误折叠和多巴胺能细胞死亡的效应因子的模型系统。
Methods. 2011 Mar;53(3):220-5. doi: 10.1016/j.ymeth.2010.12.036. Epub 2010 Dec 31.
6
[Study of molecular mechanism of anti-Parkinson's disease traditional Chinese medicine using model of Caenorhabditis elegans].利用秀丽隐杆线虫模型研究抗帕金森病中药的分子机制
Zhongguo Zhong Yao Za Zhi. 2010 Mar;35(5):661-3.
7
Modeling dopamine neuron degeneration in Caenorhabditis elegans.秀丽隐杆线虫中多巴胺能神经元变性的建模
Methods Mol Biol. 2011;793:129-48. doi: 10.1007/978-1-61779-328-8_9.
8
Parkinson's disease: insights from non-traditional model organisms.帕金森病:非传统模式生物的研究进展。
Prog Neurobiol. 2010 Dec;92(4):558-71. doi: 10.1016/j.pneurobio.2010.09.001. Epub 2010 Sep 21.
9
Anti-Parkinsonian effects of Bacopa monnieri: insights from transgenic and pharmacological Caenorhabditis elegans models of Parkinson's disease.Bacopa monnieri 对帕金森病的防治作用:来自帕金森病转基因和药理学秀丽隐杆线虫模型的研究进展。
Biochem Biophys Res Commun. 2011 Oct 7;413(4):605-10. doi: 10.1016/j.bbrc.2011.09.010. Epub 2011 Sep 8.
10
Generation of a alpha-synuclein-based rat model of Parkinson's disease.基于α-突触核蛋白的帕金森病大鼠模型的建立。
Neurobiol Dis. 2008 Apr;30(1):8-18. doi: 10.1016/j.nbd.2007.11.002. Epub 2007 Nov 13.

引用本文的文献

1
Hypoxia ameliorates neurodegeneration and movement disorder in a mouse model of Parkinson's disease.缺氧改善帕金森病小鼠模型中的神经退行性变和运动障碍。
Nat Neurosci. 2025 Aug 6. doi: 10.1038/s41593-025-02010-4.
2
Unraveling Molecular Targets for Neurodegenerative Diseases Through Models.通过模型揭示神经退行性疾病的分子靶点。
Int J Mol Sci. 2025 Mar 26;26(7):3030. doi: 10.3390/ijms26073030.
3
Animal models in biomedical research: Relevance of .生物医学研究中的动物模型:……的相关性
Heliyon. 2024 Dec 31;11(1):e41605. doi: 10.1016/j.heliyon.2024.e41605. eCollection 2025 Jan 15.
4
Cyclo(Pro-Tyr) elicits conserved cellular damage in fungi by targeting the [H]ATPase Pma1 in plasma membrane domains.环(脯氨酰-酪氨酰)通过靶向质膜域中的 [H]ATPase Pma1 引发真菌中的保守细胞损伤。
Commun Biol. 2024 Oct 3;7(1):1253. doi: 10.1038/s42003-024-06947-3.
5
Modeling of Parkinson's Disease in Different Models.不同模型中帕金森病的建模
CNS Neurol Disord Drug Targets. 2025;24(2):102-114. doi: 10.2174/0118715273326866240922193029.
6
Novel C. elegans models of Lewy body disease reveal pathological protein interactions and widespread miRNA dysregulation.新型秀丽隐杆线虫路易体病模型揭示了病理性蛋白相互作用和广泛的 miRNA 失调。
Cell Mol Life Sci. 2024 Aug 30;81(1):377. doi: 10.1007/s00018-024-05383-0.
7
Towards improved screening of toxins for Parkinson's risk.致力于改进帕金森病风险毒素筛查。
NPJ Parkinsons Dis. 2023 Dec 19;9(1):169. doi: 10.1038/s41531-023-00615-9.
8
Imaging and Genetic Tools for the Investigation of the Endocannabinoid System in the CNS.中枢神经系统内大麻素系统研究的影像学和遗传学工具。
Int J Mol Sci. 2023 Oct 31;24(21):15829. doi: 10.3390/ijms242115829.
9
Tuning Hsp104 specificity to selectively detoxify α-synuclein.调节 Hsp104 的特异性以选择性解毒 α-突触核蛋白。
Mol Cell. 2023 Sep 21;83(18):3314-3332.e9. doi: 10.1016/j.molcel.2023.07.029. Epub 2023 Aug 24.
10
Mechanistic impacts of bacterial diet on dopaminergic neurodegeneration in a α-synuclein model of Parkinson's disease.细菌饮食对帕金森病α-突触核蛋白模型中多巴胺能神经退行性变的机制性影响。
iScience. 2023 May 12;26(6):106859. doi: 10.1016/j.isci.2023.106859. eCollection 2023 Jun 16.